medigraphic.com
ISSN 1028-4818 (Electronic)

2017, Number 4

<< Back Next >>

Mul Med 2017; 21 (4)

Factors associated with the development of hypertensive nephropathy

Peña SG, Álvarez AA, Varona VM, Martínez GY

Language: Spanish
References: 40
Page: 359-379
PDF size: 343.73 Kb.


ABSTRACT

Introduction: hypertensive nephropathy is one of the lesions to target organs due to arterial hypertension with higher morbidity and mortality. Objective: to evaluate the influence of different risk factors for the development of hypertensive nephropathy.
Methods: we performed an observational and observational study of cases and witnesses in patients from hypertension consultation of the polyclinic specialties of the general university hospital Carlos M. de Céspedes, Bayamo, from January 1, 2014 to the December 31, 2016.
Results: multivariate analysis showed that a patient without control of their hypertension was the most relevant factor in increasing the risk of hypertensive nephropathy in 22.46-fold (CI: 11.915-42.341; p: 0.000) followed by left ventricular hypertrophy OR: 12.95, IC: 7.005-23.968, w: 0.000). Analysis of the ROC curve (area: 0.898; IC: 0.873-0.922; p: 0.000) showed adequate model discriminatory ability, whose calibration was acceptable (p: 0.176).
Conclusions: factors associated to hypertension, as well as some biological markers of cardiovascular risk are capable of accurately predicting the probability of developing hypertensive nephropathy; of them a model with an area under the curve with a capacity of discrimination and adequate calibration was estimated.


REFERENCES

  1. Robles Pérez Monteoliva NR, Romero B, Bureo N, Macías R, Sánchez Casado E, Cubero JJ. Enfermedad vascular hipertensiva: evolución de la incidencia en el período 1991-2007 y supervivencia antes de la enfermedad renal terminal. Nefrología [Internet]. 2010[citado 12 Ene 2016]; 30(3):304-9. Disponible en: http://www.revistanefrologia.com/es-publicacion-nefrologia-imprimir-articulo-enfermedad-vascular-hipertensiva-evolucion-incidencia-el-periodo-1991-2007-supervivencia-antes-X0211699510035834.

  2. Sánchez Celaya del Pozo M, Tranche Iparraguirre S. Documento de consenso sobre la enfermedad renal crónica. S.E.N-sem FYC. Atención Primaria [Internet]. 2014[citado 05 Ene 2016]; 46(9):453–4. Disponible en: http://www.sciencedirect.com/science/article/pii/S0212656714003084?via%3Dihub

  3. Salvador González B, Rodríguez Pascual M, Ruipérez Guijarro L, Ferré González A, Cunillera Puertolas O, Rodríguez Latre LM. Enfermedad renal crónica en atención primaria: prevalencia y factores de riesgo asociados. Atención Primaria [Internet]. 2015[citado 05 Ene 2016]; 47(4):236–45. Disponible en: https://core.ac.uk/download/pdf/82003282.pdf.

  4. Pérez Oliva Jorge F. Hemodiálisis en tiempo de huracanes y desastres en Cuba. Rev Haban Cienc Méd [Internet]. 2008 [citado 05 Ene 2016]; 7(4): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2008000400003&lng=es.

  5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J [Internet]. 2013 [citado 15 Ene 2016]; 34:2159-219. Disponible en: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/eht151.

  6. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003; 139(4):244–52.

  7. Rodríguez Beyrís RP, Rodríguez Constantín A. Hipertensión arterial en pacientes con insuficiencia renal crónica en hemodiálisis. MEDISAN [Internet]. 2009 [citado 15 Ene 2016]; 13(6). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192009000600003.

  8. Herrera Valdés R, Pérez-Oliva Díaz JF, Almaguer López M. Cómo mejorar el manejo de la enfermedad renal crónica, consideraciones y recomendaciones prácticas. Rev Haban Cienc Méd [Internet]. 2008 [citado 15 Ene 2016]; 7 (1):66-8. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2008000100009.

  9. Eknoyan G, Lameire N, Eckardt KU, Kasiske BL, Wheeler DC, Abboud OI, et al. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Summary of Recommendation Statements. Kidney Intern. 2013; 3(1):5-14.

  10. Baena-Díez JM, Javier Félix F, Grau M, Cabrera de León A, Sanz H, Leal M. Tratamiento y control de los factores de riesgo según el riesgo coronario en la población española del estudio DARIOS. Rev Esp Cardiol [Internet]. 2011[citado 15 Ene 2016]; 64(9):766-73. Disponible en: http://www.revespcardiol.org/es/content/articulo/90025317/.

  11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA [Internet]. 2003[citado 15 Ene 2016]; 289(19):2560-72. Disponible en: https://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf

  12. Dévereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977; 55(4):613-8.

  13. Aitken GR, Roderick PJ, Fraser S, Mindell JS, O’Donoghue D, Day J, et al. Change in prevalence of chronic kidney disease in England over time: Comparison of nationally representative cross-sectional surveys from 2003 to 2010. BMJ Open [Internet]. 2014 [citado 15 Ene 2016]; 4: e005480. Disponible en: http://bmjopen.bmj.com/content/4/9/e005480.

  14. Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T. Angiotensin-converting enzyme inhibitors, angiotensin II receptor Blockers and diabetes: A meta-analysis of placebo-controlled clinical trials. Am J Hypertens [Internet]. 2011 [citado 21 Ene 2016]; 24(5):2582-90. Disponible en: https://academic.oup.com/ajh/article-lookup/doi/10.1038/ajh.2011.8.

  15. Alemán-Vega G, Gómez Cabañas I, Reques Sastre L, Rosado Martín J, Palentinos-Castro E, Rodríguez Barrientos R. Prevalencia y riesgo de progresión de enfermedad renal crónica en pacientes diabéticos e hipertensos seguidos en atención primaria en la Comunidad de Madrid. Nefrología. 2017; 37(3):338–354. Disponible en: http://dx.doi.org/10.1016/j.nefro.2016.10.018.

  16. Caskey F, Steenkamp R, Ansell D. International comparison of UK registry data (Chapter 17). Nephrol Dial Transplant. 2007; 22(Suppl 7):185-93.

  17. Gorostidi M, Santamaría R, Alcázar R, Fernández-Fresnedo G, Galcerán JM, Goicoechea M, et al. Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica. Nefrología [Internet]. 2014[citado 21 Ene 2016]; 34(3):302-16. Disponible en: http://www.revistanefrologia.com/es-publicacion-nefrologia-articulo-documento-sociedad-espanola-nefrologia-sobre-las-guias-kdigo-evaluacion-el-X0211699514054048.

  18. Lozano JV, Redón J, Cea-Calvo L, Fernández-Pérez C, Navarro J, Bonet A, et al. Hipertrofia ventricular izquierda en la población hipertensa española. Estudio ERIC-HTA. Rev Esp Cardiol [Internet]. 2006[citado 21 Ene 2016]; 59(2):136-42. Disponible en: http://www.revespcardiol.org/es/hipertrofia-ventricular-izquierda-poblacion-hipertensa/articulo/13084641/.

  19. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073–81.

  20. Marshall T. The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. J Hum Hypert [Internet]. 2010 [citado 18 Ene 2016]; 24:1-8. Disponible en: http://www.nature.com/jhh/journal/v24/n10/full/jhh2009114a.html.

  21. Schulz R, Heusch G. C-reactive protein: just a biomarker of inflammation or a pathophysiological player in myocardial function and morphology? Hypertension [Internet]. 2011 [citado 15 Nov 2016]; 57:151-3. Disponible en: http://hyper.ahajournals.org/content/57/2/151.

  22. Akasheh A, Wu Y, Li Yi, Dustin LD, Wong ND, Gardin JM, et al. Association of blood pressure with left ventricular mass in untreated hypertensives in rural Yunnan province. Am J Hypertens [Internet]. 2009 [citado 22 Ene 2017]; 22:730-4. Disponible en: https://academic.oup.com/ajh/article-lookup/doi/10.1038/ajh.2009.75.

  23. Wang TD, H-H Sheu WH-H. From casual blood pressure measurement to long-term blood pressure burden: better elucidation of the association between versatile blood pressures and cardiovascular events. Hypertens Res [Internet]. 2011 [citado 22 Jul 2017]; 34:49-51. Disponible en: http://www.nature.com/hr/journal/v34/n1/full/hr2010204a.html.

  24. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010; 268(5):456-67.

  25. Windham BG, Griswold ME, Farasat SM, Ling SM, Carlson O, Egan JM, et al. Influence of leptin, adiponectin and resistin on the association between abdominal adiposity and arterial stiffness. Am J Hypertens [Internet]. 2010 [citado 21 Ene 2016]; 23:501-7. Disponible en: https://academic.oup.com/ajh/article/23/5/501/2281937/Influence-of-Leptin-Adiponectin-and-Resistin-on.

  26. Leiba A, Vinker S, Dinour D, Holtzman EJ, Shani M. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens [Internet]. 2015 [citado 25 Jul 2016]; 9(8):600–9. Disponible en: http://www.sciencedirect.com/science/article/pii/S1933171115004805.

  27. Díaz Arce D, Cardellá Rosales LL, Cabada Pérez F, Fiterre Lancis I, Montenegro Valencia MM, Souto Rodríguez Y. Hiperuricemia y factores de riesgo cardiovascular en pacientes hospitalizados. Panorama Cuba y Salud [Internet]. 2010 [citado 16 Ago 2017]; 5(2):5-12. Disponible en: http://www.revpanorama.sld.cu/index.php/panorama/article/viewFile/304/pdf.

  28. Vlachopoulos C, Xaplanteris P, Vyssoulis G, Bratsas A, Baou K, Tzamou V, et al. Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension. Am J Hypertens [Internet]. 2011[citado 16 Sep 2011]; 24:33-9. Disponible en: https://academic.oup.com/ajh/article/24/1/33/2729973/Association-of-Serum-Uric-Acid-Level-With-Aortic.

  29. Johnson RJ, Lanaspa MA, Gaucher EA. Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations. Semin Nephrol. 2011; 31(5):394–9.

  30. Peer N, Steyn K, Dennison CR, Levitt NS, Nyo MTL, Nel JH, et al. Determinants of target organ damage in black hypertensive patients attending primary health care services in Cape Town: The Hi-Hi study. Am J Hypertens [Internet]. 2008 [citado 28 Feb 2016]; 21(8):896-902. Disponible en: https://academic.oup.com/ajh/article/21/8/896/2742993/Determinants-of-Target-Organ-Damage-in-Black.

  31. Llisterri JL, Rodríguez GC, Alonso F, Banegas JR, González-Segura D, Lou S, et al. Control de la presión arterial en la población hipertensa española atendida en Atención Primaria. Estudio PRESCAP 2006. Med Clin (Barc) [Internet]. 2008 [citado 28 Feb 2016]; 130(18):681-7. Disponible en: http://www.elsevier.es/es-revista-medicina-clinica-2-articulo-control-presion-arterial-poblacion-hipertensa-13120766.

  32. García Barreto D, Álvarez González J, García Fernández R, Valiente Mustelier J, Hernández Cañero A. La hipertensión arterial en la tercera edad. Rev Cubana Med [Internet]. 2009 Jun [citado 25 May 2016]; 48(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232009000200007.

  33. Villar Álvarez F, Banegas Banegas JR, Donado Campos JM, Rodríguez Artalejo F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras: Informe de la Sociedad Española de Arteriosclerosis 2007 [Internet]. Madrid: Sociedad Española de Arteriosclerosis, 2007[citado 25 May 2016]. Disponible en: http://www.se-arteriosclerosis.org/assets/informe-sea-2007.pdf.

  34. Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT. Development and validation of a general population renal risk score. Clin J Am Soc Nephrol [Internet]. 2011[citado 25 May 2016]; 6: 1731-8. Disponible en: http://cjasn.asnjournals.org/content/6/7/1731.long.

  35. Johnson HM, Gossett LK, Piper ME, Aeschlimann SE, Korcarz CE, Baker TB, et al. Effects of smoking and smoking cessation on endothelial function 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol [Internet]. 2010 [citado 18 Mar 2016]; 55:1988-95. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947952/.

  36. He FJ, Marciniak M, Visagie E, Markandu ND, Anand V, Dalton RN, et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertens [Internet]. 2009 [citado 20 May 2016]; 54:482-8. Disponible en: http://hyper.ahajournals.org/content/54/3/482.long.

  37. Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens [Internet]. 2010 [citado 22 Ene 2016]; 23:38-45. Disponible en: https://academic.oup.com/ajh/article/23/1/38/149650/Association-of-Hypertension-Treatment-and-Control.

  38. Redon J. Global cardiovascular risk assessment: Strengths and limitations. High Blood Press Cardiovasc Prev. 2016; 23(2):87–90.

  39. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507–20.

  40. De Filippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015; 162(4):266–75.




2020     |     www.medigraphic.com